V
Vyne Therapeutics
Biotech & Life Sciences · Menlo Park, United States · Founded 2011 · IPO 2018
Late stage biopharmaceutical company focused on the development and commercialization of serlopitant for the treatment of pruritus MoreLess
VYNE Therapeutics is an entrepreneurial biopharmaceutical company focused on developing innovative and differentiated therapies to address some of the most difficult therapeutic challenges. The company leverages its existing development capabilities and a strong network of discovery and preclinical science partners to advance new medicines through the clinical pipeline. VYNE Therapeutics operates in the biopharmaceutical market, primarily serving patients with unmet medical needs. The business model revolves around the development and commercialization of proprietary therapies, generating revenue through product sales and potential partnerships or licensing agreements. The company's approach is rooted in questioning traditional assumptions and finding better solutions, driven by a culture of collaborative teamwork and independent thinking.
Keywords: biopharmaceutical, innovative therapies, proprietary, differentiated, clinical pipeline, unmet medical needs, product sales, partnerships, licensing, entrepreneurial.
Talent graph
Vyne Therapeutics's talent
Source: Dealroom Talent Intelligence.
Global footprint
Where Vyne Therapeutics has talent and traffic
team presence
Market sentiment
What the market is saying about Vyne Therapeutics
An AI-synthesized read of the highest-engagement posts about Vyne Therapeutics on X over the past 7 days. We rank by likes & retweets, ignore corporate channels, and surface the themes that broke out from real people.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See Vyne Therapeutics on the full Dealroom platform
Live deal flow, founder pedigree, hiring signals, revenue trajectory, and the full cap table.







